GLP-1(7-37) acetate is an intestinal insulin hormone that enhances glucose-induced insulin secretion.

Physicochemical Properties

Molecular Formula	C153H232N40O49
CAS #	1450806-98-0
Related CAS #	GLP-1(7-37);106612-94-6
PubChem CID	16133830
Appearance	Typically exists as solid at room temperature
Hydrogen Bond Donor Count	50
Hydrogen Bond Acceptor Count	52
Rotatable Bond Count	111
Heavy Atom Count	238
Complexity	7820
Defined Atom Stereocenter Count	30
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	During the second hour of a 2-hour 11 mM hyperglycemic clamp, infusion of GLP-1(7-37) (0.5, 5, or 50 pmol/min/kg) resulted in a dose-related rise in glucose-stimulated plasma insulin. Rats had improved concentration and a higher rate of glucose infusion [2]. GLP-1(7-37) (5 pmol/min/kg) was infused into rats kept at 11 mM glucose for 1 to 7 hours, increasing plasma insulin concentrations in comparison to rats given a vehicle injection. kept growing. 2].
Animal Protocol	Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, weighing 300 to 350 g, were administered intravenous (iv) (iv)glucose at a variable rate for 7 hrs (hrs (hours)) to maintain plasma glucose concentration at 11 mM [2]. Doses: 5 pmol/min/kg. Route of Administration: intravenous (iv) (iv)injection 1 hour to 7 hrs (hrs (hours)) [2]. Experimental Results: Plasma insulin concentrations were consistently increased compared to vehicle-injected rats. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, weighing 300 to 350 g, with plasma glucose concentration maintained at 11 mM [2]. Doses: 0.5, 5 or 50 pmol/min/kg. Route of Administration: intravenously (iv) (iv)(iv) during the second hour of a 2-hour 11 mmol/L hyperglycemic clamp. Experimental Results: Produced dose-related potentiation of glucose-stimulated increases in plasma insulin concentrations and increases in glucose infusion rates.
References	[1]. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004). [2]. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7.

Solubility Data

Solubility (In Vitro)	H2O : ~50 mg/mL (~14.64 mM)
Solubility (In Vivo)	Solubility in Formulation 1: 12.5 mg/mL (3.66 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.)